22 December 2025VideosAmericasMicheal Hebert, Greenberg Traurig | Chuck Sholtz, Verdiva Bio | Josh Mack, Halozyme | Lawrence Rozsnyai, Metsera

WATCH: Enabling success — overcoming §112 in the new era of life sciences patents

Speakers from Greenberg Traurig, Verdiva Bio, Halozyme, and Metsera discuss the implications of the USPTO’s 2024 §112 guidelines on life sciences patents.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

PTAB year in review: A shifting landscape and outlook for 2026

2 January 2026 With the unprecedented changes at the PTAB in 2025, what could the year ahead hold for the agency? Lawyers from Sterne Kessler explore.

Americas

5 ways the USPTO director is changing US innovation

24 December 2025 John Squires has rewired the country’s patents system since becoming USPTO director—but which changes are most impactful? Sarah Speight explores.

Americas

Teva scrubs 200-plus Orange Book patents after FTC turns the screw

11 December 2025 Israeli drug maker bows to FTC pressure, removing scores of “improperly listed” patents in boon for generic manufacturers.